This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Imovax
- Generic Name
- Rabies virus inactivated antigen, B
- DrugBank Accession Number
- DB10062
- Background
Inactivated rabies virus antigen B is a component of rabies vaccines used for pre- and post-exposure prophylaxis against rabies.1
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Inactivated - Synonyms
- Rabies virus strain PM-1503-3M antigen (propiolactone inactivated)
- Rabies virus vaccine wistar strain PM-1503-3M (human)
Pharmacology
- Indication
Inactivated rabies virus antigen B is indicated for pre- and post-exposure prophylaxis against rabies.1
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prophylaxis of Rabies •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Alemtuzumab. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Imovax Rabies Injection, powder, lyophilized, for suspension; Kit 2.5 [iU]/1mL Intramuscular Sanofi Pasteur Inc. 1980-06-09 2021-12-07 US 
Imovax Rabies Powder, for suspension 2.5 unit / vial Intramuscular Sanofi Pasteur Limited 1999-08-13 Not applicable Canada 
Imovax Rabies Injection, powder, lyophilized, for suspension; Kit 2.5 [iU]/1mL Intramuscular Sanofi Pasteur Inc. 2019-10-25 Not applicable US
Categories
- ATC Codes
- J06AA06 — Rabies serum
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- C4HQF74XMW
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Diarrhea / Fever / Influenza-like Illness / Upper Respiratory Disease 1 4 Completed Prevention Rabies 1 4 Completed Prevention Rabies Vaccine Adverse Reaction 1 4 Completed Treatment Rabies 1 4 Unknown Status Diagnostic Primary Immunodeficiency 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for suspension; kit Intramuscular 2.5 [iU]/1mL Powder, for suspension Intramuscular 2.5 unit / vial Injection 9 IU/ml Injection, powder, for solution 2.5 iu/mL Injection 2.5 mcg/0.5ml Powder 2.5 mcg/0.5ml Injection, powder, for suspension Intramuscular Injection, powder, for suspension Intramuscular 2.5 IU Injection, powder, for suspension Intramuscular 2.5 iu/0.5ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at November 30, 2015 21:23 / Updated at October 04, 2023 10:01